SG11201608303QA - Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer - Google Patents

Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Info

Publication number
SG11201608303QA
SG11201608303QA SG11201608303QA SG11201608303QA SG11201608303QA SG 11201608303Q A SG11201608303Q A SG 11201608303QA SG 11201608303Q A SG11201608303Q A SG 11201608303QA SG 11201608303Q A SG11201608303Q A SG 11201608303QA SG 11201608303Q A SG11201608303Q A SG 11201608303QA
Authority
SG
Singapore
Prior art keywords
dianhydrogalactitol
analogs
lung
derivatives
small
Prior art date
Application number
SG11201608303QA
Other languages
English (en)
Inventor
Jeffrey A Bacha
Dennis M Brown
Anne Steinø
Original Assignee
Del Mar Pharmaceuticals
Jeffrey A Bacha
Dennis M Brown
Anne Steinø
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Del Mar Pharmaceuticals, Jeffrey A Bacha, Dennis M Brown, Anne Steinø filed Critical Del Mar Pharmaceuticals
Publication of SG11201608303QA publication Critical patent/SG11201608303QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
SG11201608303QA 2014-04-04 2015-04-06 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer SG11201608303QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975587P 2014-04-04 2014-04-04
US201462062246P 2014-10-10 2014-10-10
PCT/US2015/024462 WO2015154064A2 (en) 2014-04-04 2015-04-06 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Publications (1)

Publication Number Publication Date
SG11201608303QA true SG11201608303QA (en) 2016-11-29

Family

ID=54241453

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608303QA SG11201608303QA (en) 2014-04-04 2015-04-06 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Country Status (13)

Country Link
US (2) US11541027B2 (ko)
EP (2) EP3125920B1 (ko)
JP (2) JP6783224B2 (ko)
KR (2) KR102456088B1 (ko)
CN (1) CN106659765B (ko)
AU (2) AU2015240465B2 (ko)
CA (1) CA2946538A1 (ko)
CL (1) CL2016002514A1 (ko)
IL (1) IL248189B (ko)
MX (1) MX2016013027A (ko)
SG (1) SG11201608303QA (ko)
TW (1) TW201713326A (ko)
WO (2) WO2015154064A2 (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
AU2011230537C1 (en) 2010-03-26 2018-08-02 Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
US20190015379A1 (en) * 2014-11-10 2019-01-17 Delmar Pharmaceuticals, Inc. Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
WO2017042634A2 (en) * 2015-09-10 2017-03-16 Del Mar Pharmaceuticals Use of dianhydrogalactitol or derivatives and analogs thereof for treatment of non-small-cell lung carcinoma, glioblastoma, and ovarian carcinoma by induction of dna damage and stalling of cell cycle
US11588149B2 (en) 2015-09-22 2023-02-21 Ii-Vi Delaware, Inc. Immobilized selenium in a porous carbon with the presence of oxygen, a method of making, and uses of immobilized selenium in a rechargeable battery
US11784303B2 (en) 2015-09-22 2023-10-10 Ii-Vi Delaware, Inc. Immobilized chalcogen and use thereof in a rechargeable battery
US11446274B2 (en) 2015-10-28 2022-09-20 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
US11870059B2 (en) 2017-02-16 2024-01-09 Consejo Superior De Investigaciones Cientificas (Csic) Immobilized selenium in a porous carbon with the presence of oxygen, a method of making, and uses of immobilized selenium in a rechargeable battery
EP3589282A4 (en) * 2017-02-28 2020-09-02 Del Mar Pharmaceuticals (BC) Ltd. USE OF DIANHYDROGALACTITOL OR ANALOGUES AND DERIVATIVES IN COMBINATION WITH A P53 MODULATOR OR PARP INHIBITOR
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN106947821B (zh) * 2017-04-11 2020-06-30 成都望路医药技术有限公司 用于诊治结肠腺癌的生物标志物
CN107447027A (zh) * 2017-09-13 2017-12-08 赵小刚 检测egfr基因g873r位点突变的试剂盒
CN107540746B (zh) * 2017-10-17 2022-07-12 北京格根生物科技有限公司 一种抗血管内皮生长因子抗体及与铁调素的融合蛋白
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
CN109517776A (zh) * 2018-11-16 2019-03-26 河北科技师范学院 一种肠炎沙门菌icdA基因缺失株及其应用
CN110927387B (zh) * 2019-11-08 2022-05-20 江苏大学 一种brca2蛋白酶联免疫双抗夹心试剂盒及其应用
CN111228307B (zh) * 2020-02-16 2020-12-29 中山大学附属第五医院 巨噬细胞在保护血管屏障中的应用以及卵巢癌腹水的预防、抑制和治疗
WO2022061001A1 (en) * 2020-09-16 2022-03-24 Splash Pharmaceuticals, Inc. Methods for patent selection and treatment of cancer
KR102560912B1 (ko) * 2020-08-26 2023-07-28 한양대학교 에리카산학협력단 엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
KR102199001B1 (ko) * 2020-09-25 2021-01-06 이화여자대학교 산학협력단 간암 진단을 위한 신규 바이오마커
CN112575005A (zh) * 2021-01-04 2021-03-30 昆明理工大学 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
US5035878A (en) 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5597798A (en) 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
ATE227991T1 (de) 1991-02-21 2002-12-15 Smithkline Beecham Corp Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5795870A (en) 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
KR970702725A (ko) 1994-04-26 1997-06-10 노부히로 나리따 비소세포 폐암 치료용 의약 조성물(Medicinal Composition as a Remedy for Nonsmall Cell Lung Cancer)
US6011069A (en) 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6733966B1 (en) 1997-06-04 2004-05-11 Rijksuniversiteit Te Leiden Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000002555A1 (en) 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
WO2001007084A1 (en) 1999-07-23 2001-02-01 Regents Of The University Of California Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20020037328A1 (en) * 2000-06-01 2002-03-28 Brown Dennis M. Hexitol compositions and uses thereof
GB0014820D0 (en) 2000-06-16 2000-08-09 Medical Res Council Methods and materials relating to plasmid vectors
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
AU2002324451A1 (en) 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2003219796A1 (en) 2002-02-20 2003-09-09 Beth Israel Deaconess Medical Center Conjugates comprising a biodegradable polymer and uses therefor
WO2003073821A2 (en) 2002-03-01 2003-09-12 Roger Williams Hospital Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
JP2005535575A (ja) 2002-04-11 2005-11-24 ザイモジェネティクス インコーポレイティッド 卵巣癌を治療するためのインターロイキン−２４の使用法
JP2005529101A (ja) 2002-04-11 2005-09-29 ザイモジェネティクス インコーポレイティッド 卵巣癌を治療するためのインターロイキン−１９の使用法
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004064748A2 (en) 2003-01-21 2004-08-05 Trustees Of Dartmouth College Compositions and methods for treatment of ovarian cancer
NZ567952A (en) 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
MXPA05010747A (es) 2003-04-11 2006-05-25 Ptc Therapeutics Inc Compuestos de acido 1,2,4-oxadiazolbenzoico y su uso para la supresion sin sentido y el tratamiento de enfermedades.
MXPA06002499A (es) 2003-09-04 2006-06-20 Aventis Pharma Inc Indoles sustituidos como inhibidores de poli (adp-ribosa) polimerasa (parp).
EP1673373A2 (en) 2003-10-02 2006-06-28 Salmedix, Inc. Indole derivatives
HUP0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
AU2005221834B2 (en) 2004-03-11 2010-09-30 4Sc Ag Sulphonylpyrroles as HDAC inhibitors
WO2005099824A1 (en) 2004-03-30 2005-10-27 Synta Pharmaceuticals, Corp. 1-glyoxylamide indolizines for treating lung and ovarian cancer
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
EA012416B1 (ru) 2004-06-30 2009-10-30 Янссен Фармацевтика Н.В. Производные замещенного 2-алкилхиназолинона как ингибиторы parp
KR101457753B1 (ko) 2004-07-22 2014-11-03 에라스무스 유니버시티 메디컬 센터 로테르담 결합 분자
WO2006023410A2 (en) 2004-08-20 2006-03-02 Buck Institute For Age Research Small molecules that replace or agonize p53 function
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP2008520742A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
DK1827437T3 (da) 2004-12-15 2012-02-13 Sigma Tau Ind Farmaceuti Kombinationer af terapeutiske midler til cancerbehandling
JP5201995B2 (ja) 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
US8404829B2 (en) 2005-01-25 2013-03-26 The Regents Of The University Of California Predictive and therapeutic markers in ovarian cancer
EP1702989A1 (en) 2005-03-16 2006-09-20 Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon Method of predicting the clinical response to cisplatin or carboplatin chemotherapeutic treatment
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
WO2006114704A2 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
JP2008547028A (ja) 2005-06-24 2008-12-25 サイファージェン バイオシステムズ， インコーポレイテッド 卵巣癌用のバイオマーカー
EP1924568A1 (en) 2005-07-15 2008-05-28 Schering Corporation Quinazoline derivatives useful in cancer treatment
US8133692B2 (en) 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
US7507536B2 (en) 2005-10-07 2009-03-24 The Johns Hopkins University Methylation markers for diagnosis and treatment of ovarian cancer
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
EP1938823A1 (en) 2005-10-19 2008-07-02 Chugai Seiyaku Kabushiki Kaisha Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble prodrug
US20090099102A1 (en) 2005-10-27 2009-04-16 The Brigham And Women's Hospital, Inc. Ginkgolides in the Treatment and Prevention of Ovarian Cancer
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
PL1951283T3 (pl) 2005-11-16 2010-12-31 Pantarhei Bioscience Bv Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
ATE549341T1 (de) 2005-12-23 2012-03-15 Ecobiotics Ltd Spiroketale
WO2007091241A1 (en) 2006-02-10 2007-08-16 Ramot At Tel Aviv University Ltd. Treatment of ovarian cancer
US7820657B2 (en) 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的***和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
WO2007149907A2 (en) 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
CA2661842C (en) 2006-09-01 2017-08-22 Cylene Pharmaceuticals, Inc. Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
CA2677046A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
US8030060B2 (en) 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
CN101678007B (zh) 2007-04-06 2013-07-03 纽罗克里生物科学有限公司 ***释放激素受体拮抗剂及其制药用途
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
JP2008295328A (ja) 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
AR066911A1 (es) 2007-06-08 2009-09-23 Janssen Pharmaceutica Nv Derivados de piperidina / piperazina
CA2691980C (en) 2007-06-29 2022-05-10 Correlogic Systems, Inc. Predictive markers for ovarian cancer
US8981131B2 (en) 2007-07-27 2015-03-17 Piramal Enterprises Limited Tricyclic compounds for the treatment of inflammatory disorders
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
ES2514517T3 (es) 2007-08-10 2014-10-28 Mitsubishi Tanabe Pharma Corporation Nueva sal de compuesto de isoquinolina y cristal de la misma
RU2511408C2 (ru) 2007-09-17 2014-04-10 Конинклейке Филипс Электроникс Н.В. Способ анализа нарушений, связанных с раком яичников
BRPI0820518B1 (pt) 2007-10-03 2021-09-28 Eisai Inc Composto e composição farmacêutica
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
US8969313B2 (en) 2007-11-02 2015-03-03 Agency For Science, Technology And Research Methods and compounds for preventing and treating a tumour
IL187247A0 (en) 2007-11-08 2008-12-29 Hadasit Med Res Service Novel synthetic analogs of sphingolipids
WO2009064444A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20090170842A1 (en) 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
EP2220073B1 (en) 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
WO2009065230A1 (en) 2007-11-23 2009-05-28 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US8476420B2 (en) 2007-12-05 2013-07-02 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
EP2229443A1 (en) 2007-12-06 2010-09-22 Novartis Forschungsstiftung, Zweigniederlassung Use of protease nexin 1 inhibitors to reduce metastasis
US8741889B2 (en) 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
WO2009097446A1 (en) 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
US8642347B2 (en) 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
EP2247600A4 (en) 2008-02-06 2011-09-14 Biomarin Pharm Inc BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
JP2011511076A (ja) 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
AU2009213689B2 (en) 2008-02-14 2014-11-20 Decode Genetics Ehf. Susceptibility variants for lung cancer
RU2494736C2 (ru) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
FR2928151B1 (fr) 2008-03-03 2010-12-31 Sanofi Aventis Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique
EP2268623B9 (en) 2008-03-17 2018-02-28 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8476026B2 (en) 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
AU2009236256B9 (en) 2008-04-14 2015-09-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
ES2584932T3 (es) 2008-04-16 2016-09-30 Assistance Publique Hôpitaux De Paris Métodos para el tratamiento, la evaluación pronóstica y la estadificación de cáncer no microcítico de pulmón
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
JP5583117B2 (ja) 2008-05-14 2014-09-03 ユニバーシティー ヘルス ネットワーク 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー
AR072092A1 (es) 2008-06-11 2010-08-04 Genentech Inc Diazacarbazoles y metodos de uso
SI2328888T1 (sl) 2008-07-09 2013-03-29 Rigel Pharmaceuticals, Inc. Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
CA2730377C (en) 2008-07-11 2017-09-19 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
PT2326650E (pt) 2008-08-06 2014-05-06 Biomarin Pharm Inc Inibidores de di-hidropiridoftalazinona de poli(adpribose) polimerase (parp)
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
CA2732658A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
KR100961410B1 (ko) 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
WO2010048330A1 (en) 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
WO2010059858A1 (en) 2008-11-19 2010-05-27 Duke University Manassantin compounds and methods of making and using same
JP5108153B2 (ja) 2008-11-26 2012-12-26 ファイザー・インク ケモカイン受容体モジュレーターとしての３−アミノシクロペンタンカルボキサミド
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8058075B2 (en) 2008-12-10 2011-11-15 University Of Utah Research Foundation Molecular fluorescence sensor for highly sensitive and selective detection of mercury
ES2490613T3 (es) 2008-12-22 2014-09-04 F. Hoffmann-La Roche Ag ARMET como marcador de cáncer
US7928105B2 (en) 2009-01-23 2011-04-19 Takeda Pharmaceutical Company Limited Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones
WO2010093435A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
ES2456275T3 (es) 2009-02-27 2014-04-21 Ambit Biosciences Corporation Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
US8969001B2 (en) 2009-03-12 2015-03-03 Rush University Medical Center Materials and methods for predicting recurrence of non-small cell lung cancer
CN101869558A (zh) * 2009-04-22 2010-10-27 北京大学 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用
PT104607B (pt) 2009-05-20 2012-03-23 Univ De Coimbra Derivados triterpenóides úteis como agentes antiproliferativos
WO2010145998A1 (en) 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
WO2011014697A1 (en) 2009-07-31 2011-02-03 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
EP2471791B1 (en) 2009-08-26 2014-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US20130203861A1 (en) 2009-09-09 2013-08-08 Golden Biotechnology Corporation Methods and compositions for treating ovarian cancer
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
BR112012006802A2 (pt) 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
AU2010303324A1 (en) 2009-10-08 2012-04-05 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011088192A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011104604A2 (en) 2010-02-23 2011-09-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
EP2548017A2 (en) 2010-03-15 2013-01-23 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
US8927538B2 (en) 2010-03-22 2015-01-06 Council Of Scientific & Industrial Research Carbazole linked pyrrolo[2,1-c][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof
HUE028751T2 (en) 2010-04-27 2017-01-30 Pharma Mar Sa Unsaturated, anticancer steroid lactones at position 8 (7)
US8980933B2 (en) 2010-05-05 2015-03-17 Universitat Bayreuth Combretastatin analogs for use in the treatment of cancer
CN104725509B (zh) 2010-05-18 2018-12-18 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
US8957065B2 (en) 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012006563A2 (en) 2010-07-08 2012-01-12 The Administrators Of The Tulane Educational Fund Novel daidzein analogs as treatment for cancer
EP2593451B1 (en) 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
US20120171694A1 (en) 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
CA2807498C (en) 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
EP2605650A4 (en) * 2010-08-18 2014-05-21 Del Mar Pharmaceuticals COMPOSITIONS AND METHODS FOR IMPROVING PROFIT TREATMENT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL INCLUDING hexitols SUBSTITUTED AS DIANHYDROGALACTITOL COMPOSITIONS AND DIACÉTYLDIANHYDROGALACTITOL AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL AS DIANHYDROGALACTITOL AND DIACÉTYLDIANHYDROGALACTITOL
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
KR20180031823A (ko) 2010-09-01 2018-03-28 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
EP2611443A2 (en) 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer
WO2012037573A1 (en) 2010-09-17 2012-03-22 Indiana University Research And Technology Corporation Small molecule inhibitors of replication protein a that also act synergistically with cisplatin
WO2012047570A1 (en) 2010-09-28 2012-04-12 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
KR101497113B1 (ko) 2010-10-20 2015-03-03 한국생명공학연구원 Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EA201370107A1 (ru) 2010-11-11 2013-11-29 Редкс Фарма Лимитед Производные лекарственных средств
EA026168B1 (ru) 2010-11-12 2017-03-31 Эндосайт, Инк. Способы лечения рака
AR083916A1 (es) 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
EP3153510B1 (en) 2010-12-03 2020-05-06 Emory University Fused azines as chemokine cxcr4 receptor modulators and uses related thereto
WO2012076942A1 (en) 2010-12-06 2012-06-14 Council Of Scientific & Industrial Research 4-aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
TWI441824B (zh) 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
CA2821984A1 (en) 2010-12-17 2012-06-21 Des R. Richardson Thiosemicarbazone compounds and use in the treatment of cancer
WO2012096832A2 (en) 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
US8975267B2 (en) 2011-01-26 2015-03-10 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
US8946409B2 (en) 2011-01-27 2015-02-03 Board Of Regents, The University Of Texas System Polycyclic β lactam derivatives for the treatment of cancer
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
WO2012116328A2 (en) 2011-02-24 2012-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
DE112012000990T5 (de) 2011-02-24 2014-03-27 Vermillion, Inc. Biomarker-Panels, Diagnostische Verfahren und Testkits für Eierstockkrebs
WO2012116050A2 (en) 2011-02-24 2012-08-30 Eternity Bioscience Inc. Phosphorus containing compounds as protein kinase inhibitors
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
WO2012117246A1 (en) 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
ES2734673T3 (es) 2011-03-02 2019-12-11 Nestle Sa Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
US20140357605A1 (en) 2012-03-22 2014-12-04 Bristol-Myers Squibb Company Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
AU2012240448A1 (en) 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
US8933116B2 (en) 2011-04-04 2015-01-13 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
CA2837727C (en) 2011-06-24 2019-12-03 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
CN105254616B (zh) 2011-07-27 2017-10-17 阿斯利康(瑞典)有限公司 取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
US9499530B2 (en) 2011-08-01 2016-11-22 Hangzhou Minsheng Institutes For Pharma Research Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
US9045450B2 (en) 2011-08-10 2015-06-02 Zhen Yang Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
AU2012311640B2 (en) 2011-09-19 2017-04-13 Alfasigma S.P.A. New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments
US20140309184A1 (en) 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
WO2013043962A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
CN103958506B (zh) 2011-09-27 2017-02-22 诺华股份有限公司 用作突变idh抑制剂的3‑嘧啶‑4‑基‑噁唑烷‑2‑酮化合物
TW201326162A (zh) 2011-09-28 2013-07-01 Euro Celtique Sa 氮芥子氣衍生物
US8946445B2 (en) 2011-10-12 2015-02-03 Nanjing Allgen Pharma Co., Ltd. Heterocyclic molecules as apoptosis inducers
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140357594A1 (en) 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
SG11201401895WA (en) 2011-11-03 2014-05-29 Millennium Pharm Inc Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
AR088642A1 (es) 2011-11-03 2014-06-25 Genentech Inc Compuestos de piperazina alquilados
CN104203238A (zh) 2011-11-10 2014-12-10 纪念斯隆-凯特琳癌症中心 用亚苄基苯甲酰肼治疗卵巢癌
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
CN103917233B (zh) 2011-11-11 2018-11-16 伊莱利利公司 用于卵巢癌的组合疗法
CN104302292A (zh) 2011-11-22 2015-01-21 德西费拉制药有限责任公司 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物
JP2015504048A (ja) 2011-12-21 2015-02-05 ニューヨーク・ユニバーシティ タンパク質分解抵抗性水素結合サロゲートヘリックス
CA2860723A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
EP2804850B1 (en) 2012-01-19 2018-08-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN110711188A (zh) * 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
PT2810937T (pt) 2012-01-31 2017-03-03 Daiichi Sankyo Co Ltd Derivado de piridona
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
RS54689B1 (en) 2012-03-06 2016-08-31 Cephalon, Inc. CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR
US9266828B2 (en) 2012-03-16 2016-02-23 Sanford-Burnham Medical Research Institute Inhibitors of Furin and other pro-protein convertases
RU2677245C2 (ru) 2012-03-20 2019-01-16 Новартис Аг Комплексная терапия
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
KR20140144726A (ko) 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
WO2013152301A1 (en) 2012-04-05 2013-10-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. O-glycan pathway ovarian cancer signature
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
WO2013170115A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
US8921367B2 (en) 2012-05-31 2014-12-30 Amgen Inc. Use of AMG 900 for the treatment of cancer
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
MX367055B (es) * 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
CN104968353B (zh) 2012-11-13 2017-12-22 博研医药开发股份有限公司 吉西他滨前药及其用途
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
US8946246B2 (en) 2012-11-16 2015-02-03 New Mexico Technical Research Foundation Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
JP6273621B2 (ja) 2012-12-21 2018-02-07 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
SG11201506243XA (en) 2013-02-14 2015-09-29 Bristol Myers Squibb Co Tubulysin compounds, methods of making and use
EP2970285B1 (en) 2013-03-11 2019-04-17 AbbVie Inc. Fused tetracyclic bromodomain inhibitors
MX2015012386A (es) 2013-03-13 2016-02-03 Abbvie Inc Inhibidores de la cinasa cdk9.
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2016512816A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
US10413538B2 (en) 2013-05-08 2019-09-17 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
US20140371158A1 (en) 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
AU2014100435A4 (en) 2013-06-17 2014-05-29 Macau University Of Science And Technology A novel treatment of Gefitinib-resistant non-small-cell lung cancer
BR112015029972A2 (pt) 2013-07-03 2017-07-25 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US20150065526A1 (en) 2013-09-05 2015-03-05 Emory University Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
US8927717B1 (en) 2014-02-14 2015-01-06 National Defense Medical Center Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof

Also Published As

Publication number Publication date
KR102359214B1 (ko) 2022-02-07
CA2946538A1 (en) 2015-10-08
JP2017512841A (ja) 2017-05-25
KR20220021013A (ko) 2022-02-21
EP3294284A4 (en) 2019-02-20
KR20160132130A (ko) 2016-11-16
EP3125920B1 (en) 2020-12-23
US20190269646A9 (en) 2019-09-05
MX2016013027A (es) 2017-05-23
US11541027B2 (en) 2023-01-03
AU2016262079A8 (en) 2018-01-18
CN106659765A (zh) 2017-05-10
IL248189A0 (en) 2016-11-30
EP3294284A1 (en) 2018-03-21
KR102456088B1 (ko) 2022-10-19
IL248189B (en) 2020-05-31
CN106659765B (zh) 2021-08-13
AU2015240465A1 (en) 2016-10-27
EP3125920A4 (en) 2018-03-07
AU2016262079A1 (en) 2018-01-04
AU2015240465B2 (en) 2020-02-27
WO2015154064A3 (en) 2016-01-14
CL2016002514A1 (es) 2017-12-15
JP2018515613A (ja) 2018-06-14
EP3125920A2 (en) 2017-02-08
WO2015154064A2 (en) 2015-10-08
US20180140571A1 (en) 2018-05-24
TW201713326A (zh) 2017-04-16
US20160008316A1 (en) 2016-01-14
WO2016183331A1 (en) 2016-11-17
JP6783224B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
IL248189A0 (en) Use of dianhydrogalacticol type substances to treat lung cancer and ovarian cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL266766B (en) Dioxolane analog of uridine for cancer treatment
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL252192A0 (en) Dihydrogalactitol together with radiation for the treatment of non-small cell lung cancer and glioblastoma multiforme
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
IL247940B (en) Treatment of cancer damaged by 1brca or resistant cancers
IL263835A (en) Exosome-guided treatment of cancer
GB201408297D0 (en) Treatment of cancer
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
GB201417456D0 (en) Treatment of cancer
ZA201704589B (en) Compounds for the treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201402602D0 (en) Therapeutic uses of flavin-containing monooxygenase 3
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417465D0 (en) Treatment of cancers